Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.63 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196393 | 0.92 | PTPN11 (0.57) | PTPN11S1PR3PTPN1PTPN6CREBBP | |
| SCHEMBL1749820 | 0.88 | PTPN11 (0.63) | PTPN11CREBBPALDH1A1HPGDGRM2 | |
| SCHEMBL7568390 | 0.87 | PTPN11 (0.51) | PTPN11S1PR3PTPN1PTPN6CREBBP | |
| SCHEMBL641868 | 0.86 | CREBBP (0.64) | CREBBPHDAC1HDAC8HDAC6AKR1C3 | |
| SCHEMBL2056260 | 0.85 | CREBBP (0.51) | PTPN11PTPN1CREBBPALDH1A1HPGD | |
| SCHEMBL1505079 | 0.85 | AKR1C3 (0.52) | PTPN11CREBBPHDAC1HDAC8HDAC6 | |
| SCHEMBL10497745 | 0.84 | KMT2A (0.55) | CREBBPHDAC1 | |
| SCHEMBL7565287 | 0.83 | ALDH1A1 (0.54) | PTPN11S1PR3CREBBPALDH1A1AKR1C3 | |
| SCHEMBL16190196 | 0.83 | PTPN11 (0.59) | PTPN11S1PR3PTPN1PTPN6TP53 | |
| SCHEMBL16168746 | 0.82 | PTPN11 (0.60) | PTPN11S1PR3ALDH1A1HPGDGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372656-B1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LTD (GB) | 2005-06-22 | — | — | EP | disclosed |
| US-6784185-B2 | PYRAZOLO(4,3-D) PYRIMIDINONE COMPOUNDS USEFUL AS CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES (CGMP PDES) INHIBITOR | PFIZER INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1372656-A1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198223-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002074312-A1 | PYRAZOLO`4,3-D.PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198223-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PTPN11 2175/4885S1PR3 649/4885PTPN1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.